News ReleaseView printer-friendly version << Back
Paratek Pharmaceuticals Promotes Evan Loh, M.D. to Chief Executive Officer; Michael Bigham to Assume Role of Executive Chairman
- Adam Woodrow Promoted to President & Retains Chief Commercial Officer Position
- Randy Brenner Promoted to
Chief Development & Regulatory Officer
“I am honored to have the opportunity to lead Paratek through the next phase of growth as we work to continue the successful launch and commercialization of NUZYRA in the U.S and establish Paratek as the leader in the anti-infective space,” said Dr. Loh “My primary focus will be on creating significant value for shareholders by maintaining a clear focus on our commercialization and life-cycle expansion opportunities for NUZYRA, and ultimately ensuring patients have access to this potential life-saving therapy.”
Dr. Loh has nearly 20 years of experience as a senior executive in the pharmaceutical industry, most recently serving as Paratek’s Chief Operating Officer since
In connection with the appointment of Dr. Loh as Chief Executive Officer, Michael Bigham will remain with Paratek and assume the role of Executive Chairman where he will continue to provide strategic guidance and leadership for the organization.
“I would like to thank Evan for his steadfast service and consummate professionalism over the years. He has worked in close partnership with me these past five years as we built Paratek from a small private company into a leading public antibiotics company with two approved antibiotics, NUZYRA and SEYSARA.” said Mr. Bigham. “Evan and the team have demonstrated an ability to discover, develop and successfully launch new medicines. I look forward to continue working closely with Evan, in partnership with Adam and Randy, to lead Paratek into the next phase of its growth.”
Paratek has submitted a marketing authorization application of omadacycline in the European Union. Paratek has entered into a collaboration agreement with Zai Lab for the development and commercialization of omadacycline in the greater China region and retains all remaining global rights.
Under a research agreement with the U.S. Department of Defense, omadacycline also is being studied against pathogenic agents causing infectious diseases of public health and biodefense importance, including plague and anthrax.
SEYSARA® (sarecycline) is an FDA-approved product with respect to which Paratek has exclusively licensed certain rights in the United States to Almirall, LLC. SEYSARA is currently being marketed by Almirall in
Recognizing the serious threat of bacterial infections, Paratek is dedicated to providing solutions that enable positive outcomes and lead to better patient stories.
For more information, visit www.ParatekPharma.com or follow @ParatekPharma on Twitter.
NUZYRA (omadacycline) is a novel antibiotic with both once-daily intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). A modernized tetracycline, NUZYRA is specifically designed to overcome tetracycline resistance and exhibits activity across a spectrum of bacteria, including Gram-positive, Gram-negative, atypicals, and other drug-resistant strains.
Please see full Prescribing Information for NUZYRA at www.NUZYRA.com.
Forward Looking Statements
This press release contains forward-looking statements including statements related to our overall strategy, products, prospects and potential. All statements, other than statements of historical facts, included in this press release are forward-looking statements, and are identified by words such as "advancing," "expect," "look forward," "anticipate," "continue," and other words and terms of similar meaning. These forward-looking statements are based upon our current expectations and involve substantial risks and uncertainties. We may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in our forward-looking statements and you should not place undue reliance on these forward-looking statements. Our actual results and the timing of events could differ materially from those included in such forward-looking statements as a result of these risks and uncertainties. These and other risk factors are discussed under "Risk Factors" and elsewhere in our Annual Report on Form 10-K for the year ended
Investor and Media Relations:
Source: Paratek Pharmaceuticals